Ocutec's Unique Selling Points
Episode 12, Apr 11, 2022, 09:33 AM
Scott Carnegie (Chairman of Ocutec) joins the Deepbridge Discovery Podcast to discuss the foundations of Ocutec, recent highlights of the company, uniqure selling points of Ocutec and what the future looks like for Ocutec as a soft contact lens manufacturer.
About Ocutec:
Ocutec Ltd. is a Scotland-headquartered corporation, specializing in the development and commercialization of soft contact lenses utilising polyethylene glycol (PEG) polymer chemistry as the basis of its highly biocompatible contact lenses.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.
About Ocutec:
Ocutec Ltd. is a Scotland-headquartered corporation, specializing in the development and commercialization of soft contact lenses utilising polyethylene glycol (PEG) polymer chemistry as the basis of its highly biocompatible contact lenses.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.